NCT03533036 is a NA clinical trial of applied VR headset in First Trimester Abortion, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03533036?

NCT03533036 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03533036?

Interventions in NCT03533036: applied VR headset.

What condition does NCT03533036 study?

NCT03533036 studies First Trimester Abortion, Virtual Reality.

Is NCT03533036 still recruiting?

NCT03533036 is currently completed. Last updated 4 October 2019.

Are results published for NCT03533036?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-10-04 · How we verify

NCT03533036

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Virtual Reality Experience in First Trimester D&C

Completed NA Results posted Last updated 4 October 2019

What this trial tests

NA trial testing applied VR headset in First Trimester Abortion in 30 participants. Completed in 30 September 2018.

Timeline

13 December 2017

Primary endpoint
18 September 2018

30 September 2018

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	30
Start date	13 December 2017
Primary completion	18 September 2018
Estimated completion	30 September 2018
Sites	1 location across United States

Drugs / interventions tested

applied VR headset

Conditions studied

First Trimester Abortion — all drugs for First Trimester Abortion →
Virtual Reality — all drugs for Virtual Reality →

Sponsor

University of California, Los Angeles

Who can join

18 and older, female only, with First Trimester Abortion or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Able to Use VR Device Throughout the Entire Duration of First Trimester Surgical Abortion. Primary · 15 minutes

Number of participants able to use VR device throughout the entire duration of first trimester surgical abortion.

Group	Value	95% CI
Virtual Reality Intervention	6

Change in Procedure Related Anxiety as Assessed by the Visual Analog Scale (VAS). Secondary · 30 min

Mean change in procedure related anxiety score as assessed by the Visual Analog Scale (VAS). The Visual Analog Scale is a 11 point scale ranging from 0 to 10. 0 indicates the least amount of discomfort or anxiety whereas 10 represents the most amount of discomfort or anxiety. Participants were surveyed on their level of discomfort prior to and after the procedure. The difference of these scores was taken and the average of each group is presented in as a result.

Group	Value	95% CI
Virtual Reality Intervention	-3.97	± 3.20
Control Arm	-2.71	± 2.89

Sponsor's own description

Virtual reality (VR) has been used in health care settings to decrease anxiety and pain. This project is a feasibility study to evaluate whether virtual reality can be used in the setting of a first trimester pregnancy termination by D\&C and whether the use of virtual reality (VR) headsets can help decrease anxiety for patients during this procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for First Trimester Abortion

Currently open trials in the same condition.

NCT05360186 — New Cross-linked Hyaluronan Gel to Prevent Adhesion After USG-MVA: RCT · NA · recruiting
NCT04708808 — The Effect of Music Therapy Under Ultrasound Guided Manual Vacuum Aspiration · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03533036 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 4 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03533036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing